FDA ap­proves Lex­i­con’s heart-fail­ure drug af­ter de­feat in di­a­betes

The FDA on Fri­day ap­proved Lex­i­con’s heart fail­ure drug so­tagliflozin fol­low­ing a string of set­backs for the phar­ma com­pa­ny, in­clud­ing an FDA re­jec­tion in di­a­betes …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER